Non-small cell lung cancer (NSCLC) remains a cause of significant morbidity and mortality, despite significant advances made in its treatment using immune checkpoint inhibitors (ICIs) over the last decade; while a minority experience prolonged responses with ICIs, benefit is limited for most patients. The development of multiplexed antibody-based (MAB) spatial tissue imaging technologies has revolutionised analysis of the tumour microenvironment (TME), enabling identification of a wide range of cell types and subtypes, and analysis of the spatial relationships and interactions between them. Such study has the potential to translate into a greater understanding of treatment susceptibility and resistance, factors influencing prognosis and recurrence risk, and identification of novel therapeutic approaches and rational treatment combinations to improve patient outcomes in the clinic. Herein we review studies that have leveraged MAB technologies to deliver novel insights into the TME of NSCLC.
尽管过去十年间免疫检查点抑制剂（ICIs）在非小细胞肺癌（NSCLC）治疗领域取得重大进展，该疾病仍是导致高发病率与死亡率的重要原因；虽然少数患者通过ICIs获得长期应答，但多数患者的临床获益仍有限。基于多重抗体的空间组织成像技术（MAB）的发展彻底改变了肿瘤微环境（TME）的分析范式，使得对多种细胞类型及亚型的精准识别成为可能，并能解析其空间关系与相互作用机制。此类研究有望深化对治疗敏感性及耐药机制的理解，揭示影响预后与复发风险的关键因素，并为临床开发新型治疗策略及优化联合治疗方案提供依据，从而改善患者临床结局。本文系统综述了运用MAB技术揭示NSCLC肿瘤微环境特征的最新研究进展。
肿瘤(癌症)患者之家